Disease Applications

Myelodysplastic Syndrome (MDS)/Myeloproliferative Disorders (MPD)

  1. Detection/enumeration of abnormal myeloblasts
  2. Detection of abnormal maturing myeloid cells and monocytes
  3. Generation of a flow cytometric score for prognostic purposes [1-3]
  4. JAK2 point mutation detection
  5. Detection of possible myelosuppressive lymphoid abnormalities

Non-Hodgkin Lymphoma

  1. Diagnosis of B, T, or NK cell lymphoma
  2. Staging/monitoring with molecular fingerprint/cell sorting
  3. Gene rearrangement studies of non-viable specimens not analyzable by flow cytometry or for retrospective fingerprint comparison

Acute Leukemia

  1. Diagnosis and classification
  2. Promyelocytic leukemia phenotype triggers STAT with same day molecular analysis for PML-RARA
  3. Identification of AML arising from MDS
  4. Residual disease assessment during and after therapy
  5. Quantitative monitoring for cytogenetic abnormalities including t(15;17), t(8;21), inv(16), t(9;22), t(12;21), t(4;11), and t(1;19)

Chronic Myelogenous Leukemia (CML)

  1. Classification of blast crisis by immunophenotyping
  2. Diagnosis/confirmation with cytogenetics
  3. Quantitative PCR for monitoring response to Gleevec™
  4. Sequencing of the Bcr-Abl for is available for Gleevec resistant cases

Plasma Cell Neoplasms

  1. Diagnosis of plasma cell neoplasms/MGUS/lymphoplasmacytic lymphoma
  2. Clonality light chain restriction/gene rearrangement
  3. Monitoring residual disease with molecular fingerprint
  4. All plasma cell neoplasms are enriched for FISH analysis for plasma cell isolation. This gives us a higher detection rate of abnormal plasma cells at their mature state. We sort for plasma cells in any MM case that is lower than 20%, going as low as 0.1%.
  5. Microarray studies are available on all plasma cell neoplasms.

Paroxysmal Nocturnal Hemaglobinuria

  1. Identification of missing phosphatidylinositol glycan anchored proteins
  2. Differentiation of MDS from aplastic anemia
  3. Detection of genetic polymorphisms

1. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008 Feb 1; 111(3): 1067.

2. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003 Jul 1; 102(1): 394.

3. Westers T, Chamuleau MED, Westra AH. Changes in flow cytometric dysplasia score during treatment with erythropoietin/G-CSF reflects responses in low/int-I myelodysplastic syndromes.  . Leuk Res 2007; 31 (suppl 1):S90.

This is a unique website which will require a more modern browser to work!

Please upgrade today!